All In Biotech

Free tool

FAERS Monitor: Follistim Aq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021211 or its brand name (Follistim Aq, Follitropin Alfa/Beta). Reports on generic versions are filed under their own applications.

Reports

1,143

Serious

148

13% of reports

Hospitalization

65

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event176
  • headache118
  • poor quality device used91
  • abdominal distension80
  • product packaging quantity issue74
  • product quality issue69
  • fatigue66
  • incorrect dose administered66
  • injection site pain62
  • nausea61
  • product dose omission issue54
  • circumstance or information capable of leading to medication error51
  • device malfunction43
  • ovarian hyperstimulation syndrome43
  • maternal exposure during pregnancy32

Reports by year received

View as table
YearReports
20054
20084
20105
201111
20124
201319
20146
20158
201615
201727
201863
2019217
2020144
2021208
2022144
202320
202418
202521
2026205

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,016 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal43345.9257.214,179
poor quality device usedSignal91168.4138.214,849
product packaging quantity issueSignal74121.397.28,656
circumstance or information capable of leading to medication errorSignal5127.821.31,292
no adverse eventSignal17617.915.62,811
abdominal distensionSignal8014.111.4966
device malfunctionSignal4311.38.4393
product quality issueSignal699.47.4509
maternal exposure during pregnancySignal326.64.7147
incorrect dose administeredSignal665.34.2230
injection site painSignal623.72.9122
headacheSignal1183.52.9211
product dose omission issueSignal543.42.689
fatigue661.61.213
nausea611.41.17

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.